Intussusception Risk after Rotavirus Vaccination in U.S. Infants

Details

Basic Details

Date

Thursday, February 6, 2014

Type

Publication

Medical Product

Rotarix

RotaTeq

rotavirus vaccine

Health Outcome(s)

intussusception

Description

This article describes the findings of a study conducted to evaluate the risk of intussusception associated with two Rotavirus vaccines, Rotateq (RV5) and Rotarix (RV1), in infants 5 to 30.9 weeks of age in the United States.

Materials

The New England Journal of Medicine, Volume 370. No 6, February 2014, Pages 503-512 DOI:10.1056/NEJMoa1303164

Additional Information

Information

Time Period

2004–2011

Population / Cohort

All infants 5 to 30.9 weeks of age

Data Source(s)

Mini-Sentinel Distributed Database (MSDD)

Contributors

Author(s)

W. Katherine Yih PhD, MPH; Tracy A. Lieu MD, MPH; Martin Kulldorff PhD; David Martin MD, MPH; Cheryl McMahill-Walraven PhD, MSW; Richard Platt MD, MSc; Nandini Selvam PhD, MPH; Mano Selvan PhD; Grace M. Lee MD, MPH; Michael Nguyen MD

Corresponding Author

W. K. Yih, Department of Population Medicine, Harvard Pilgrim Healthcare Institute and Harvard Medical School, 401 Park Drive, Suite 401 East, Boston, MA 02215, U.S.A. E-Mail: katherine_yih@harvardpilgrim.org